Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Unnecessary Use of Heavily Marketed Medicines: A Randomized Controlled Trial of Computerized Prescribing Alerts and Clinician Education
Brief Summary: Prescribing decisions by clinicians are often thought to be simple: a patient's clinical problem leads a prescriber to choose the optimal treatment. However, many factors other than the patient's condition affect prescribing decisions, including the marketing of pharmaceuticals. Clinicians are subjected to direct "detailing" by representatives of the pharmaceutical industry, advertisements in medical journals and requests for specific treatments from patients, who are increasingly exposed to direct-to-consumer (DTC) advertising. These influences, often based on biased or inaccurate information, contribute to a variety of problems in prescribing, including the unnecessary use of expensive, heavily marketed medications.

Overcoming these influences requires innovative approaches. The movement toward widespread adoption of electronic health records (EHRs) and electronic prescribing presents new opportunities to educate both clinicians and patients at the time of medication prescribing. This project, endorsed by the AHRQ-supported Centers for Education and Research on Therapeutics (CERTs; www.certs.hhs.gov) and the U.S. Food and Drug Administration (FDA), aims to test the effectiveness of computerized prescribing alerts and state-of-the-art educational outreach to reduce the unnecessary use of heavily marketed medications. A second goal is to improve clinicians' knowledge of industry marketing practices, so that they can more effectively assess information provided by drug companies. Thus, the study has two specific aims:

Specific Aim 1: To assess whether computerized prescribing alerts linked electronically to patient educational material can reduce prescribing of heavily marketed medications.

Specific Aim 2: To assess whether group academic detailing increases clinicians' knowledge about industry marketing practices and increases the effect of prescribing alerts.


Options:
A: Arm Label: mHealth midwives; Type: EXPERIMENTAL; Interventions: Device: mHealth | Arm Label: mHealth midwives - control; Type: ACTIVE_COMPARATOR; Interventions: Device: mHealth | Arm Label: Pregnant Women; Type: ACTIVE_COMPARATOR; Interventions: Device: mHealth | Intervention Type: DEVICE; Name: mHealth; Assigned to Arm(s): Pregnant Women, mHealth midwives, mHealth midwives - control
B: Arm Label: Computerized Alerts; Type: EXPERIMENTAL; Interventions: Behavioral: Computerized alerts | Arm Label: Alerts PLUS Detailing; Type: EXPERIMENTAL; Interventions: Behavioral: Alerts Plus Detailing | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Computerized alerts; Assigned to Arm(s): Computerized Alerts | Intervention Type: BEHAVIORAL; Name: Alerts Plus Detailing; Assigned to Arm(s): Alerts PLUS Detailing
C: Arm Label: dashboard team care intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Dashboard Intervention | Arm Label: usual diabetes team control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Diabetes Care | Intervention Type: BEHAVIORAL; Name: Diabetes Dashboard Intervention; Assigned to Arm(s): dashboard team care intervention | Intervention Type: BEHAVIORAL; Name: Usual Diabetes Care; Assigned to Arm(s): usual diabetes team control
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: CDS for psychotropic drug management | Intervention Type: DEVICE; Name: CDS for psychotropic drug management; Assigned to Arm(s): 2

Answer: B